Starling Oncology forecasts FY2026 revenue of $650-670 million
Reuters2026/09/09 10:38- Starling Oncology forecast FY26 revenue of USD 650-670 million, based on guidance reiterated in its Aug. 6, 2026 2Q26 release.
- Adjusted EBITDA expected at USD 2-7 million for FY26, implying a low single-digit margin on the revenue outlook.
- Forecast follows FY25 revenue of USD 503 million, with revenue mix led by specialty pharmacy at 54%.
- Growth backdrop includes 2.3 million value-based care lives under contract, 60+ payor contracts, 300,000+ encounters in 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Block applies for a national trust bank license to custody BTC and stablecoins
Over $70 billions amassed in a single day, reaching a new high since June! Global companies rush to issue bonds ahead of the Federal Reserve rate hike
After setting a new record on Tuesday for the busiest global issuance day since June, with total fundraising exceeding 70 billions of dollars, companies are accelerating their return to the bond market. They aim to lock in funds before borrowing costs rise any further.
Standard Life publishes transcript of HY 2026 results presentation
Beng Kuang Marine issues 218,570 shares from warrant exercises at S$ 0.22 each
Crypto prices
More
